A major aim of this team is to develop innovative strategies to stimulate cytosolic delivery of nucleic acids in lung-related target cells for the treatment of pulmonary pathologies with a clear unmet medical need, including obstructive lung diseases and respiratory infections. To reach this goal, the team of prof. Raemdonck focuses on (i) exploiting endogenous materials for drug delivery, such as pulmonary surfactant, (ii) repurposing of small molecular drugs as adjuvants to promote nucleic acid delivery and (iii) improving nanomedicine design for in vivo use. The delivery approaches emerging from these projects are developed as platform technologies that also find applications outside of the lung in e.g. ex vivo cell engineering and in vitro transfection. To date, Prof. Raemdonck (co-)authored > 90 peer-reviewed publications, many of which in leading journals of the field (Nature Nanotechnology, Nature Biotechnology, Advanced Materials, ACS Nano, Journal of Controlled Release, Biomaterials). The Lung Delivery Team collaborates with many (inter)national research groups worldwide, including the Department of Biochemistry and Molecular Biology of the Complutense University of Madrid, the Department of Pharmaceutics of Utrecht University, the Department of Bioengineering of Imperial College London and the Department of Cell Research and Immunology of Tel Aviv University.